The 36-month beta value for NVNO is at 1.27. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NVNO is 17.48M, and currently, shorts hold a 2.91% of that float. The average trading volume for NVNO on November 21, 2024 was 130.64K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NVNO) stock’s latest price update
enVVeno Medical Corporation (NASDAQ: NVNO)’s stock price has dropped by -6.65 in relation to previous closing price of 3.61. Nevertheless, the company has seen a loss of -0.88% in its stock price over the last five trading days. accesswire.com reported 2024-11-20 that 85% Clinical Meaningful Benefit Responder Rate 7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort 75% Median Reduction in Pain (VAS) 87% Median Ulcer Area Reduction 97% Target Vein Patency Rate Improvement in All Patient Reported Quality-of-Life Indicators Company to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time – Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium in New York City. The definitive one-year data supports the application submitted earlier this week by enVVeno Medical seeking pre-market authorization (PMA) from the U.S. Food and Drug Administration (FDA) to market and sell the VenoValve in the U.S. Among the data being presented at VEITH are: Eighty five percent (85%) of the subjects in the VenoValve pivotal study that reached the one-year milestone achieved a clinically meaningful benefit of a three (3) or more point improvement in revised Venous Clinical Severity Score (rVCSS).
NVNO’s Market Performance
enVVeno Medical Corporation (NVNO) has experienced a -0.88% fall in stock performance for the past week, with a -2.60% drop in the past month, and a -37.48% drop in the past quarter. The volatility ratio for the week is 7.13%, and the volatility levels for the past 30 days are at 5.21% for NVNO. The simple moving average for the past 20 days is -1.57% for NVNO’s stock, with a -31.06% simple moving average for the past 200 days.
NVNO Trading at -8.68% from the 50-Day Moving Average
After a stumble in the market that brought NVNO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.65% of loss for the given period.
Volatility was left at 5.21%, however, over the last 30 days, the volatility rate increased by 7.13%, as shares surge +1.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.56% lower at present.
During the last 5 trading sessions, NVNO fell by -0.88%, which changed the moving average for the period of 200-days by -20.71% in comparison to the 20-day moving average, which settled at $3.42. In addition, enVVeno Medical Corporation saw -34.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVNO starting from Alavi Hamed, who sale 8,334 shares at the price of $6.22 back on Mar 13 ’24. After this action, Alavi Hamed now owns 0 shares of enVVeno Medical Corporation, valued at $51,837 using the latest closing price.
Stock Fundamentals for NVNO
Current profitability levels for the company are sitting at:
- -28.4 for the present operating margin
- 0.34 for the gross margin
The net margin for enVVeno Medical Corporation stands at -25.78. The total capital return value is set at -0.49. Equity return is now at value -58.76, with -54.12 for asset returns.
Based on enVVeno Medical Corporation (NVNO), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -46.8. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -57.79.
Currently, EBITDA for the company is -25.02 million with net debt to EBITDA at 0.75. When we switch over and look at the enterprise to sales, we see a ratio of 51.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.01.
Conclusion
In conclusion, enVVeno Medical Corporation (NVNO) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
